ArticleInfection and immunity2003
Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 4 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication.BMC gastroenterology · 2025Pooled it
- Efficacy and safety ofFrontiers in cellular and infection microbiology · 2025Pooled it
- The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.BMC infectious diseases · 2023Pooled it
- Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.World journal of gastroenterology · 2010Pooled it
- Effects of supplementing with Saccharomyces boulardii on vonoprazan-amoxicillin dual therapy for naive Helicobacter pylori infection: a randomized controlled trial.BMC gastroenterology · 2026Trial
- Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea.World journal of gastroenterology · 2006Trial
- Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora.Pediatric nephrology (Berlin, Germany) · 2006Trial
- Molecular Genetics and Probiotic Mechanisms of Saccharomyces cerevisiae var. boulardii.Probiotics and antimicrobial proteins · 2026Review
- The probiotic yeastFrontiers in microbiology · 2026Article
- Article
- The Athlete Gut Microbiome: A Narrative Review of Multi-Omics Insights and Next-Generation Probiotic Strategies.Nutrients · 2025Review
- Article
- Evaluation of Single and Multi-Strain Probiotics with Gentamicin AgainstMicroorganisms · 2025Article
- Probiotics and the intestinal tight junction barrier function.Frontiers in cell and developmental biology · 2025Review
- Supplementation with Combined Additive Improved the Production of Dairy Cows and Their Offspring with Maintenance of Antioxidative Stability.Antioxidants (Basel, Switzerland) · 2024Article
- A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- Modulating the Microbiome for Crohn's Disease Treatment.Gastroenterology · 2023Review
- The efficacy and safety ofTherapeutic advances in gastroenterology · 2023Article
- Article
- Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome.Nutrients · 2021Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterohemorrhagic Escherichia coli (EHEC) infections are associated with the modification of tight-junction permeability and synthesis of proinflammatory cytokine interleukin-8 (IL-8). In a previous study, it was demonstrated that EHEC-induced IL-8 secretion is due to the involvement of the mitogen-activated protein kinase (MAPK), AP-1, and NF-kappaB pathways. In this study, we investigated the effect of the yeast Saccharomyces boulardii on EHEC infection in T84 cells. For this purpose, cells were (i) incubated with bacteria and yeast at the same time or (ii) incubated overnight with yeast cells that were maintained during infection or eliminated by several washes before infection. Coincubation is sufficient to maintain the transmonolayer electrical resistance (TER) of EHEC-infected cells, whereas the preincubation of cells with the yeast without elimination of the yeast during infection is necessary to significantly decrease IL-8 secretion. We thus analyzed the mechanisms of S. boulardii action. We showed that S. boulardii has no effect on EHEC growth or on EHEC adhesion. Kinetics studies revealed that EHEC-induced myosin light chain (MLC) phosphorylation precedes the decrease of TER. ML-7, an MLC kinase inhibitor, abolishes the EHEC-induced MLC phosphorylation and decrease of TER. Studies show that S. boulardii also abolishes EHEC-induced MLC phosphorylation. We demonstrated that the preincubation of cells with S. boulardii without washes before EHEC infection inhibits NF-kappaB DNA binding activity, phosphorylation and degradation of IkappaB-alpha, and activation of the three members of a MAPK group (extracellular signal-regulated protein kinases 1 and 2, p38, and c-jun N-terminal kinase). These findings demonstrate that S. boulardii exerts a preventive effect on EHEC infection by (i) interfering with one of the transduction pathways implicated in the control of tight-junction structure and (ii) decreasing IL-8 proinflammatory secretion via inhibition of the NF-kappaB and MAPK signaling pathways in infected T84 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.